Retina · 2015 · 25 citations · 24 references
Health ProfessionsOphthalmologyPharmacotherapyOcular DiseaseOcular ImagingOphthalmic SurgeryAge-related Macular DegenerationMacular DegenerationMacular DiseaseMacular DisordersOptical Coherence TomographyRetinal ImagingAcuity In Macular DiseaseAnti-vegf Ocular TherapyIntravitreal Anti-vascular Endothelial Growth Factor TherapyRetinal Thickness AnalysisVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitorsVisual Acuity ImprovementVitreomacular Traction Syndrome
In Brief Purpose: To evaluate the effect of vitreomacular traction (VMT) on visual acuity outcomes and central retinal thickness (CRT) measurements after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for treatment of exudative age-related macular degeneration (AMD). Methods: In this retrospective series, the authors evaluate the clinical records and optical coherence tomography of 34 eyes of 32 patients, with VMT confirmed on optical coherence tomography at baseline, to assess the effects of VMT on anti-VEGF therapy for newly diagnosed exudative wet AMD. Best-corrected visual acuity at baseline, 1, 3, 6, 9, and 12 months and CRT at baseline, 3, 6, and 12 months were assessed. Comparison was made with a control group of 29 eyes of 28 patients with wet AMD and no VMT on optical coherence tomography and with key variable-dosing studies for anti-VEGF in exudative AMD (CATT, HARBOR, PrONTO, SUSTAIN, and Gupta et al). Results: Best-corrected visual acuity results showed a visual acuity improvement that peaked at 3 months with 2.47 letters, well below other variable-dosing studies for anti-VEGF therapy in exudative AMD. This was then followed by a steady decline with mean best-corrected visual acuity at 12 months ending below the baseline level (−1.00 letters) compared with a gain of 9.39 letters in the control group at 12 months. Comparison of the mean CRT in the VMT group between baseline and 12 months showed no significant difference (P = 0.67), whereas the PrONTO study and control groups showed a highly significant difference at 12 months compared with baseline (P < 0.001). Mean CRT values at 6 months and 12 months were essentially at baseline levels (0.26 μm, −0.62 μm, respectively). Conclusion: Vitreomacular traction at baseline, existing concurrently with newly diagnosed exudative AMD treated with intravitreal anti-VEGF therapy on a variable-dosing regime, was associated with poorer visual outcomes and a decreased response to reduction in CRT, compared with a control group of wet AMD without VMT and compared with major variable-dosing studies for intravitreal anti-VEGF in exudative AMD. In patients with age-related macular degeneration treated with anti-vascular endothelial growth factor therapy on a variable-dosing regime, concurrent vitreomacular traction was associated with a less favorable visual outcome and less of a reduction in central retinal thickness compared with a control group of treated wet age-related macular degeneration without vitreomacular traction and compared with major variable-dosing regime studies of exudative age-related macular degeneration treated with anti-vascular endothelial growth factor therapy.
24
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text
Medicine, Ophthalmology, Surgery +12
Complement Factor H Polymorphism in Age-Related Macular Degeneration
Robert J. Klein, Caroline J. Zeiss, Emily Y. Chew et al. · Science · 2005 · 4.5K citations
Medicine, Immunology, Ophthalmology +14
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier, David M. Brown, Victor Chong et al. · Ophthalmology · 2012 · 2.5K citations